Industry Research

ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.

Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.

ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.

ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.

A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

Understanding which attributes industry peers feel are important can help in the process of CRO selection.

When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.

ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.

2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.

Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.

The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.

The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.

Integration with eClinical software applications will drive IRT (interactive response technology) enhancements, but it is important to many study sponsors that IRT be delivered though companies that specialize in this technology.

What is the effect of a near-record volume of drug approvals? Just think about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities.

Using data from several market research reports, Industry Standard Research analyzed preferred provider arrangements across clinical development, eClinical, and contract manufacturing industries. Go to ISRreports.com/free-industry-resources to see the full infographic, which includes data for the contract manufacturing and eClinical markets.

Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries, has collected information from outsourcing decision makers via an online survey regarding their selection and evaluation of CROs.

Over the past several decades, the practice of outsourcing has evolved from transactional, client-vendor relationships where cost savings were the primary focus, to preferred provider relationships with pre-vetted companies to start up projects quickly and then to relationships more strategic in nature to gain access to technologies, skills, or expertise not possessed in-house.